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ABSTRACT
Prevalence and Predictors of Polypharmacy in
Adolescents who have Engaged in Sexually Abusive Behaviors
by
Rebecca Gilley
Polypharmacy, or the concurrent use of multiple medications, is associated with detrimental
outcomes for patients and has gathered increasing attention within the scientific clinical
literature. Pediatric populations warrant special consideration for the practice of polypharmacy,
as medication effects are more pronounced in youth and adverse effects may have a lasting
impact on development. This dissertation study examined psychotropic prescribing practices in a
sample of adolescents who have engaged in sexually abusive behaviors, a subset of justiceinvolved youth who are at risk for polypharmacy. General prescribing trends were examined, and
a principle components analysis involving variables associated with risk of polypharmacy was
conducted. Results indicated that polypharmacy was common, with many youth being prescribed
medications at a young age. Use of risky medications such as antipsychotics was also prevalent,
even for individuals without psychosis. Analyses suggested that behavioral issues, trauma and
residential instability, and complex psychological concerns were significantly associated with
polypharmacy outcomes. Clinical implications of findings are discussed.

2

TABLE OF CONTENTS

ABSTRACT ................................................................................................................................ 2
LIST OF TABLES ...................................................................................................................... 5
LIST OF FIGURES ..................................................................................................................... 6
Chapter 1. Introduction ............................................................................................................... 7
Prevalence and Contributing Factors ....................................................................................... 8
Negative Outcomes associated with Polypharmacy .............................................................. 11
Psychotropic Medication ADRs ........................................................................................ 12
Psychiatric Polypharmacy in Youth ...................................................................................... 13
Psychotropic Medication ADRs in Youth ......................................................................... 14
Specific Subpopulations at Risk for Psychotropic Polypharmacy ........................................ 17
Individuals with Complex Medical & Mental Health Needs............................................. 17
Individuals who Experience Trauma ................................................................................. 19
Justice-Involved Populations ............................................................................................. 21
Current Study......................................................................................................................... 23
Research Aim 1 .................................................................................................................. 24
Research Aim 2 .................................................................................................................. 25
Research Aim 3 .................................................................................................................. 25
Chapter 2. Methods ................................................................................................................... 26
Data Collection & Sample ..................................................................................................... 26
Variables ................................................................................................................................ 27
Research Aim 1 .................................................................................................................. 32
Research Aim 2 .................................................................................................................. 33
Research Aim 3 .................................................................................................................. 35
Chapter 3. Results ..................................................................................................................... 36
Research Aim 1 ..................................................................................................................... 37
Research Aim 2 ..................................................................................................................... 42
Research Aim 3 ..................................................................................................................... 49
Chapter 4. Discussion................................................................................................................ 52
General Trends in Prescribing ............................................................................................... 53
Principal Component Analysis .............................................................................................. 55
3

Changes in Prescribing .......................................................................................................... 59
Summary & Clinical Implications ......................................................................................... 60
Limitations ............................................................................................................................. 62
Conclusion ............................................................................................................................. 64
References ................................................................................................................................. 65
VITA ......................................................................................................................................... 79

4

LIST OF TABLES

Table 1. Independent Variables, Coding Mechanisms, and Descriptive Statistics ....................... 28
Table 2. Dependent Variables, Coding Mechanisms, and Descriptive Statistics ......................... 31
Table 3. Regression Analysis Summary for Age at Admission Predicting Number of
Medication Classes (n = 282)....................................................................................... 38
Table 4. Descriptive Statistics of Polypharmacy Variables by Diagnostic Category ................... 40
Table 5. Regression Analysis Summary for Number of Diagnoses Predicting Age of Initiation
of Psychotropic Medications (n = 118) ........................................................................ 41
Table 6. Regression Analysis Summary for Number of Diagnoses Predicting Number of
Medication Classes (n = 283)....................................................................................... 41
Table 7. Pattern Matrix of Final Solution of Principal Component Analysis ............................... 43
Table 8. Component Correlation Matrix of Four-Component Solution ....................................... 45
Table 9. Regression Analysis Summary for PCA Components Predicting Age of Initiation of
Psychotropic Medication (n = 118) .............................................................................. 46
Table 10. Regression Analysis Summary for PCA Components Predicting Number of
Medication Classes (n = 283)....................................................................................... 47
Table 11. Regression Analysis Summary for PCA Components Predicting Antipsychotic
Medications (n = 283) .................................................................................................. 48
Table 12. Regression Analysis Summary for PCA Components Predicting ADHD/Stimulant
Medications (n = 283) .................................................................................................. 49
Table 13. Frequencies of Variable Representing Change in Number of Medication Classes
Prescribed After Admission to Treatment Facility (n = 278) ...................................... 50
Table 14. Regression Analysis Summary for Number of Diagnoses Predicting Change in
Medication Classes Post-Admission (n = 278) ............................................................ 51
Table 15. Regression Analysis Summary for PCA Components Predicting Change in
Medication Classes Post-Admission (n = 278) ............................................................ 51

5

LIST OF FIGURES

Figure 1. Scree Plot of the First Iteration of Principal Components Analysis .............................. 42
Figure 2. Histogram Representing the Change in Number of Medication Classes After
Admission to the Treatment Facility ............................................................................ 50

6

Chapter 1. Introduction
Polypharmacy, or the use of multiple medications to treat complex physical and
psychological conditions, is a critical topic across varied aspects of healthcare research. The
practice of polypharmacy has become increasingly common, and its potentially negative
consequences continue to be important considerations for pharmacological care. Despite the
growing literature base investigating polypharmacy, the definition of this practice varies widely.
As indicated by the prefix poly, researchers generally agree that the word indicates the use of
multiple medications to treat someone at a given time. However, some studies utilize a threshold
of two or more medications (e.g., Kukreja et al., 2013), while others use thresholds of up to five
or ten concurrent medications (e.g., Gnjidic et al., 2017; Guthrie et al., 2015). Others have also
distinguished between polypharmacy involving various drug types, such as concurrent use of a
blood pressure medication and antidepressant, versus polypharmacy specific to a given target
problem, such as concurrent use of two antidepressants to treat depression.
As other researchers have noted, the inconsistency in definitions and inclusion criteria for
polypharmacy is a major limitation within this research base (Guthrie et al., 2015; Rhee &
Rosenheck, 2019). Comparisons across studies that utilize different definitions may be
inappropriate, and it becomes unclear as to which types of polypharmacy (or perhaps all of them)
are most likely to yield detrimental results. Differentiating between within-class and betweenclass polypharmacy is highly beneficial (Rhee & Rosenheck, 2019). Within-class comedication
is more likely to be previously studied and supported as an evidence-based practice, whereas
between-class comedication can produce drug-drug interactions given that the medications work
in different ways. Additionally, between-class polypharmacy may be common in psychiatric
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populations, as these patients evidence high rates of comorbidity, requiring multiple medication
classes for differential presenting concerns (Mojtabai & Olfson, 2008).
Despite these variations in defining polypharmacy itself, the practice of providing
concurrent prescription of multiple medications has increased over time for both adult and youth
populations (e.g., Bourgeois et al., 2006; Haider et al., 2007). Polypharmacy practices for
pediatric populations have unique considerations, such as lasting side effects, differences in
developmental stages, and off-label prescribing. Other specific subpopulations evidence further
risk of polypharmacy, such as individuals with complex health needs (Brenner et al., 2014;
Duffy et al., 2005), those who experience trauma (Anda et al., 2007; Koskenvuo & Koskenvuo,
2014), and justice-involved populations (Griffiths et al., 2012; Lyons et al., 2013). Some children
may fall into multiple at-risk categories. Youth who have engaged in sexually abusive behaviors
represent a unique group that evidences risk for polypharmacy in multiple ways, though there is
currently no research specific to polypharmacy practices in this population. More information is
needed to better understand prescribing practices for these youth, as they may be particularly
vulnerable to possible detrimental outcomes associated with polypharmacy. I will first review
information on the general practice of polypharmacy, followed by literature specific to
subpopulations related to this area of interest.
Prevalence and Contributing Factors
Prescribing trends indicate the rise of polypharmacy prescription practices, with
longitudinal studies noting increases in prevalence over time (Bourgeois et al., 2006; Guthrie et
al., 2015; Haider et al., 2007). An estimated 31% of adult patients are prescribed two or more
drugs, and 11-35.8% are prescribed five or more drugs (Gu et al., 2010; Qato et al., 2016). The
proportion of adult patients taking five or more medications more than doubled between 1995
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and 2005 (Bourgeois et al., 2006). Although these rates are noteworthy, it is important to specify
that polypharmacy is not altogether negative. In many cases, polypharmacy may be clinically
appropriate and extremely helpful for the patient. However, it is important for providers to weigh
the risks of negative consequences in their decision-making.
The current study focuses on psychotropic polypharmacy, which pertains to the use of
multiple prescribed medications to alter a patient’s psychological state and functioning and to
specifically treat forms of psychopathology. The rise of psychotropic polypharmacy has been
associated with various root causes. For example, Ghaemi (2002) identified five associated
contributing factors: 1) scientific advances illustrating medication efficacy; 2) economic impacts
of pharmaceutical companies and corresponding market; 3) influences of medications and their
efficacy on revisions to the diagnostic system for psychological disorders, resulting in many
diagnoses that overlap in symptoms; 4) political influences from regulations by agencies like the
U.S. Food and Drug Administration; and 5) U.S. cultural attitudes, in that Americans often prefer
medication over behavioral therapies, stemming from their desire for more immediate relief from
ailments. This latter factor is also evident from the push for medication over more long-term
solutions like individual therapy, with an increasing number of psychiatrists specializing in
pharmacotherapy and fewer offering psychosocial or behavioral therapy options (Mojtabai &
Olfson, 2008).
Polypharmacy may also result from characteristics of the medications themselves. Some
psychotropic medications have a delayed onset of action, during which other medications may be
prescribed to provide some degree of symptom reduction (Möller et al., 2014; Preskorn & Lacey,
2007). Psychological disorders are also sometimes described as treatment resistant (e.g.,
depression), such that some medications produce a non-response (Millan, 2014; Möller et al.,
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2014). This leads to a trial-and-error approach in which various medications may be added or
removed at varying intervals. Sometimes medications are added solely for the purpose of treating
the side effects of another medication, creating a cycle of continual prescription and
corresponding polypharmacy (Kukreja et al., 2013; Möller et al., 2014).
The complexity of psychological disorders, which often involve multiple interacting and
reciprocal neurobiological systems, is yet another factor that contributes to polypharmacy. This
lack of simplicity complicates pharmacological treatment, as there are often not singular targets
but rather multiple interacting systems that produce a cascading effect (Möller et al., 2014).
Additionally, psychotropic medication efficacy research is influenced by irrational or unrealistic
expectations of treatment outcomes (Ghaemi, 2002; Möller et al., 2014). That is, treatment
success is often measured by elimination of symptoms or significant symptom reduction, rather
than outcomes that acknowledge the chronicity of psychological distress (e.g., increased quality
of life, longer periods of time between relapses/major episodes, improved functionality). For
more severe and persistent psychological disorders, a goal of total elimination of symptoms may
not be attainable. However, these unrealistic beliefs may lead to prescriptions being added to
address various symptoms of a disorder, rather than helping the patient understand and cope with
the chronicity of their condition and develop goals more consistent with expected outcomes.
Thus, while there are factors that may indicate that psychotropic polypharmacy is
appropriate, there are also negative consequences that may be related to use of multiple
medications at once. Prescribers should be aware of these in order to determine if additional
medications would either benefit or instead adversely impact their patients.
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Negative Outcomes associated with Polypharmacy
There are various negative outcomes associated with polypharmacy. First, multiple
medications can quickly complicate a pharmacological regimen. Medications commonly have
specifiers, for example: administer at morning or night, administer with or without food, cannot
be administered at the same time as other medications, double the quantity if a dose is missed,
take as needed versus regularly. Increasing the number of medications inherently increases the
amount of information a patient must remember. Ample studies that have demonstrated that
polypharmacy is associated with poor medication adherence (e.g., Inauen et al., 2017; Markotic
et al., 2013; Viktil et al., 2007). Relatedly, when patients do experience positive outcomes
following being medicated, the confounding effects of different drugs makes it more difficult for
medical professionals to understand which drug is causing relief (Kukreja et al., 2013).
Second, polypharmacy increases risk for adverse drug reactions (ADRs), with increasing
numbers of concurrent drugs producing a dose-response relationship with risk of ADRs
(Bourgeois et al., 2010; Viktil et al., 2007). Common ADRs include gastrointestinal disturbance,
fatigue, dizziness, and cardiovascular problems (Khalil & Huang, 2020). Although often acute,
these side effects can sometimes lead patients to the emergency room, with ADRs accounting for
2-3% of all emergency department visits for unintentional injuries (Bourgeois et al., 2010;
Budnitz et al., 2006). ADRs can also be potentially fatal. One meta-analysis estimated that 4.6%
of deaths in the United States may be the result of an adverse drug event (ADE), of which ADRs
are a subsample (Lazarou et al., 1998). The risk of ADRs may be one reason why polypharmacy
has been linked to increased risk of mortality (e.g., Gómez et al., 2014; Mansur et al., 2008).
Third, multiple medications also increase the risk for drug-drug interactions (Guthrie et
al., 2015; Haider et al., 2007; Qato et al., 2016). One drug may change the pharmacokinetics of
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another drug, meaning there could be a change in the nature, magnitude, and/or duration of the
drug’s effect (Kukreja et al., 2013; Preskorn & Lacey, 2007). These drug interactions not only
complicate the mechanisms of pharmacotherapy but can also lead to ADRs, which may then be
more severe. Multiple drugs may have the same adverse effects or work on the same systems,
compounding such problems. In extreme cases, this could even cause an unintentional overdose,
especially if drugs are sedating or nervous system depressants. Drug-drug interactions and
related pharmacokinetics can also lead to the cumulative toxicity of substances that are not
harmful at low doses but can be lethal if accumulated within the body (Kukreja et al., 2013).
Psychotropic Medication ADRs
Psychotropic medications should be uniquely considered, as their ADRs can be
significant and impact both physical and psychological systems. Common ADRs of such
medications include changes in mental status, behavior, or mood (Olfson, 2015). Sedatives and
anxiolytics may cause impaired cognitive functioning, reduced mobility, and falls. Stimulants are
associated with cardiovascular ADRs, namely heart palpitations. Hypersensitivity and sensory
disturbances are the most common ADRs for antidepressants, and patients also frequently
experience sexual dysfunction (Olfson, 2015; Resnik, 2008).
Antipsychotics are one drug class for which ADRs can be particularly burdensome.
Psychological side effects include impaired concentration, confusion, attention deficit, and
memory impairment (Lieberman, 2004; Möller et al., 2014). Physical side effects include dry
mouth, constipation, urinary retention, bowel obstruction, dilated pupils, blurred vision,
increased heart rate, and decreased sweating. Weight gain is also extremely common.
Antipsychotics often induce extrapyramidal side effects (EPS), which encompass tardive
dyskinesia, dystonia, akathisia, and parkinsonism. EPS can be debilitating for the patient, as they
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impact everyday motor tasks and coordination, communication, and activities of daily living
(D'Souza & Hooten, 2020). First-generation antipsychotics are linked to a higher risk of EPS in
comparison to their second-generation counterparts, though rates for both range from 4-67%
(Divac et al., 2014; Janno et al., 2004). In one study, polypharmacy increased the likelihood of
anti-EPS treatment two-fold (Carnahan et al., 2006), indicating that multiple medications
exacerbate the risk of such ADRs.
These considerations are important given that psychiatric polypharmacy is common; an
estimated 60% of psychiatric patients in outpatient settings are prescribed multiple psychotropic
medications (Mojtabai & Olfson, 2008). Polypharmacy increases the risk for these psychotropicspecific ADRs as well as the aforementioned negative outcomes. Questions of risk may be
especially pertinent for populations in which conditions may be more challenging to treat, or for
individuals with more complex clinical presentations.
Psychiatric Polypharmacy in Youth
Many studies investigating polypharmacy research focus on geriatric and older adult
populations, as these subpopulations evidence higher prevalence of health problems and
corresponding polypharmacy (Rambhade et al., 2012). However, the issues related to
polypharmacy are not limited to adults. Newer research on polypharmacy in youth and small
children is emerging, although this topic is less frequently studied in these populations. This is
problematic, as the evidence base guiding polypharmacy prescription practices in youth is much
more limited, even though the practice still routinely occurs. Studies estimate that 4-84% of
youth are prescribed at least one psychotropic medication, and 14-52% of youth are prescribed
two or more psychotropic medications, with rates varying across different study designs,
treatment settings, and age groups (Chen et al., 2011; Comer et al., 2010; Dharni & Coates,
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2018; Duffy et al., 2005; Medhekar et al., 2019; Olfson et al., 2002). Longitudinal trends indicate
that psychotropic prescription and polypharmacy rates are increasing over time (McIntyre &
Jerrell, 2009).
Most medication trials are first validated in adult populations, and an evidence base for
youth populations may not yet be established for some medications (Crismon & Argo, 2009;
Roberts et al., 2003). For many psychotropic medications, use in children under the age of 12 is
considered off-label prescribing, as efficacy in this age group has not been established in
research (Jensen et al., 1994; Malone et al., 1999). This lack of evidence is concerning as studies
of polypharmacy note that when research is lacking, prescribers use their own clinical judgment
and past anecdotal experience for decision-making (Möller et al., 2004). This could be
particularly problematic given individual variability in children due to physiological
developmental differences, even amongst youth in the same age range. There may also be
significant differences across ethnicities and genders (Goldberg & Wagner, 2019). Additionally,
the fact that youth are still developing at the time of psychotropic drug exposure requires medical
professionals to adjust reference values typically used for monitoring side effects of such
medications, such as body mass index and thyroid function thresholds (Correll & Carlson, 2006).
This can complicate the process of assessing ADRs in children. Children may also be less likely
to speak up about ADRs, perhaps due to a lack of understanding given their young age or
because they feel unequipped to discuss such matters with healthcare providers (Goldberg &
Wagner, 2019).
Psychotropic Medication ADRs in Youth
There are multiple potential ADRs associated with psychotropic medication use in
children. Metabolic side effects may come in various forms, resulting in weight gain, weight

14

loss, Type 2 Diabetes Mellitus, and dyslipidemia (Correll & Carlson, 2006; Jerrell, 2010;
Kubiszyn et al., 2012). Endocrine-related ADRs can result in thyroid dysfunction, growth
retardation, and reduction in adult height, as well as polycystic ovarian syndrome in female
patients (Correll & Carlson, 2006). Appetite disturbances may result in increases or decreases in
appetite, dyspepsia, nausea, and vomiting (Jerrell, 2010; Kubiszyn et al., 2012). Other common
ADRs include dizziness, sweating, blurred vision, insomnia, fatigue, sedation, concentration
difficulties, impulsivity, and mood disturbances (Kubiszyn et al 2012; Lee et al 2015).
As with adult populations, antipsychotic use in children can be associated with more
severe side effects. Youth are at higher risk than adults for antipsychotic-induced
hyperprolactinemia, weight gain, and other metabolic abnormalities (Correll & Carlson, 2006).
These metabolic side effects are especially troubling given that obesity and related concerns in
childhood are linked to a variety of cardiovascular issues in adulthood, and obesity can have a
negative impact on a child’s mental health (Pringsheim, Panagiotopoulos et al., 2011). Youth
prescribed these medications also commonly experience EPS, such as dystonia, akathisia, and
parkinsonism (Crismon & Argo, 2009; Kubiszyn et al., 2012; Pringsheim, Doja et al., 2011).
Other possible side effects include sedation, drooling, a decrease in absolute neutrophil count,
and even cataracts (Pringsheim, Panagiotopoulos et al., 2011).
Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed as
antidepressants and also have pediatric-specific concerns. SSRIs can sometimes lead to
“activation” in youth, which is a cluster of symptoms associated with hyperarousal including
impulsivity, restlessness, and insomnia (Luft et al., 2018). Youth aged 12 years or younger may
be most at risk for activation ADRs (Garcia-Delgar et al., 2018). Other known ADRs associated
with SSRIs for youth include tremors, tics, enuresis, sedation, affective blunting, profound
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apathy, and akathisia (Peters & Connolly, 2012). Another concern of pediatric antidepressant use
is increased risk of suicidal thoughts, which has resulted in the so-called black box criteria that
must be reviewed with all patients and families before antidepressant therapy is initiated (Peters
& Connolly, 2012).
Given the risk of these significant side effects and the complications that may occur
during different developmental stages in pediatric populations, there have been published
guidelines intended to help guide psychotropic medication practice for these individuals. For
example, pharmacotherapy is not usually recommended as the only treatment intervention for
youth with mental health diagnoses; psychotherapy and community support should be added
when possible (American Academy of Child and Adolescent Psychiatry [AACAP], 2012)
Researchers caution against psychotropic prescription for very young children aged six and
under (Crismon & Argo, 2009). Initiation of medications during this time period has been
associated with continued, chronic use, in addition to the concerns of consuming powerful
medications during a time of extensive developmental growth (dosReis et al., 2014). Guidelines
indicate attaining a detailed past medical and family history, a full medical/physical examination,
completion of formal psychological assessment and diagnosis, and a thorough informed consent
process with both patient and parents about the risks and benefits of such medications before
prescription (Goldberg & Wagner, 2019; Gringras & McNicholas, 1999; McNally et al., 2007).
Careful monitoring of ADRs and development (e.g., height, weight) should occur at regular time
intervals (Gringras & McNicholas, 1999; Pringsheim, Panagiotopoulos et al., 2011). It is also
recommended to try to decrease dosages to the lowest amounts, especially when medications
have been prescribed for a longer time period (AACAP, 2012). Despite these recommendations,
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there are often children who are prescribed high-risk medications such as antipsychotics without
a prior psychological assessment or psychotherapy involvement (Olfson et al., 2010).
There are thus many additional considerations for prescribing psychotropic medications
in youth compared to adults. For both populations, these risks quickly add up when multiple
medications are involved. It is important for prescribers to be aware of groups at higher risk for
psychotropic medication and polypharmacy in order to best implement the aforementioned
guidelines.
Specific Subpopulations at Risk for Psychotropic Polypharmacy
Regardless of the patient’s age, there are other risk factors that increase the probability of
an individual being prescribed multiple medications. These include complex or multiple health
needs, comorbidity, experiences of trauma and adversity, a history of behavioral issues like
aggression, and justice-system involvement. These additional risks are discussed further below.
Individuals with Complex Medical & Mental Health Needs
Not surprisingly, multiple diagnoses increase the risk for polypharmacy. Increasing
comorbidity typically indicates more complex symptomology and thus a greater number of needs
that can be addressed through pharmacology. Comorbidity has been consistently associated with
polypharmacy within various populations, both adult and pediatric (Comer et al., 2010; Duffy et
al., 2005; McIntyre & Jerrell, 2009; Medhekar et al., 2019; Ninan et al., 2014; Rambhade et al.,
2012). Individuals with higher symptom severity are also often prescribed multiple medications
(Brenner et al., 2014). It is important to note that although these individuals may have increased
need for polypharmacy to target multiple issues, their comorbid conditions inherently complicate
the risk of ADRs and non-targeted systems being affected by medications. Thus, prescribers
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must be cautious to ensure that specific medications are not contraindicated due to another
condition.
There are also specific diagnoses indicative of chronic symptomology that are more
likely to be treated with polypharmacy, including serious and persistent mental illness (SPMI;
e.g., bipolar disorder and schizophrenia) and treatment-resistant depression (Duffy et al., 2005;
Gallego et al., 2012; Millan, 2014). SPMI diagnoses are characterized by more severe symptoms
such as psychosis and are associated with profound negative effects on activities of daily living
and social functioning. Diagnoses designated treatment resistant have not been effectively treated
thus far, indicating that multiple treatment avenues may be needed to properly address
symptoms. Suicidality and self-harm are also markers of more serious symptomology, which
often leads to pharmacotherapy and potentially polypharmacy (Fontanella et al., 2009).
Recent hospitalizations, including both general hospitalization for medical needs
(Jokanovic et al., 2015; Rambhade et al., 2012) and inpatient psychiatric hospitalization
(Björkenstam et al., 2013; Duffy et al., 2005; Gallego et al., 2012), are also associated with
polypharmacy. Medication changes are common during hospitalization. Studies estimate that 4778% of adolescents in inpatient psychiatric care have at least one medication change during their
stay (Dean et al., 2006; Fontanella et al., 2009), and about 60% of such youth have medications
added to their existing pre-hospitalization regimen (Blader, 2006). Physicians within the hospital
often prescribe various medications to address an acute concern, but patients often continue these
medications after they are released from the hospital. Additionally, longitudinal data illustrates
that medications continue to be added up to 12 months post-discharge (Blader, 2006). Thus,
individuals with multiple diagnoses, more complicated symptomology, or concerns requiring

18

hospitalization are more likely to be prescribed multiple medications than those without such
characteristics.
Individuals who Experience Trauma
Trauma has also been linked to the prescription of psychotropic medications and
polypharmacy. Adverse childhood experiences (ACEs), or experiences of abuse, neglect, and
household dysfunction that occur prior to age 18, have been associated with increased rates of
psychotropic medication prescription in adulthood (Anda et al., 2007; Koskenvuo & Koskenvuo,
2014) and other mental health outcomes that can lead to psychotropic pharmacotherapy,
including alcoholism, drug abuse, depression, psychosis, and suicide attempts (Felitti et al.,
1998; Varese et al., 2012; Whitfield et al., 2005). In fact, research has indicated a dose-response
relationship between ACEs and such outcomes, meaning each additional ACE further increases
the risk of detrimental outcomes (Anda et al., 2007; Felitti et al., 1998).
A history of trauma or maltreatment can also complicate diagnosis, as those who experience
multiple or chronic traumatic stressors often have comorbid issues or may not fully meet
diagnostic criteria for post-traumatic stress disorder (PTSD; Crismon & Argo, 2009; John et al.,
2019). Diagnostic inaccuracy (i.e., overdiagnosis, underdiagnosis, and misdiagnosis) is common,
as responses to trauma are often overlooked or misinterpreted (Hodas, 2006). For example,
children who experience trauma may present with concentration problems, hyperactivity, and
impulsivity that could be incorrectly identified as attention-deficit hyperactivity disorder
(ADHD) if proper screening for trauma is not conducted. Youth diagnosed with ADHD are often
prescribed stimulant medications, which may be contraindicated for those who have symptoms
stemming from traumatic experiences. Similarly, adolescents may engage in substance abuse to
self-medicate following traumatic experiences in childhood. This may lead to adults and
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treatment providers focusing on the substance abuse (an externalizing behavior that is considered
delinquent) as the central issue, rather than the trauma that precipitated such abuse. Substance
abuse also increases the likelihood of revictimization and PTSD, creating a cycle of abuse,
psychiatric symptoms, and illicit substance use. Subsequent treatment that is not traumainformed may not be sufficient to alleviate the underlying problems, and as such many evidencebased treatments targeted at this subset of youth address both issues concurrently. Other
ineffective interventions for youth who have experienced trauma include those that are punitive
or shaming (Hodas, 2006), which may exacerbate existing symptoms.
Children who experience ACEs often become involved with child welfare systems and
may be placed into foster care. These youth in foster care experience higher rates of psychotropic
medication prescription as well as polypharmacy in comparison to non-systems youth, which is
particularly true of those who enter care at a young age and those with higher symptom severity
(Brenner et al., 2014; dosReis et al., 204; Zito et al., 2008). Many youth in foster care experience
multiple out-of-home placements and for long periods of time. This residential instability
presents unique obstacles for psychotropic medication prescription practices. Each movement to
a new placement represents a disruption in care, which also presents emotional and attachment
problems for the youth (Longhofer et al., 2011) as well as potential disruptions in access to care
or care from a known medical provider. An important contributor to medication adherence is the
presence of a consistent caregiver to assist the child with consent and management, which these
youth often lack. Additionally, these children experience multilayered stigma of being victimized
and lacking a “real” family, such that the additional stigma of psychotropic medication can feel
even more ostracizing. As Longhofer and colleagues (2011) summarize, “Foster children
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experience triple jeopardy: they endure maltreatment, they experience abrupt removal from
families, and they live daily with prospects of unpredictable and unplanned transitions” (p. 399).
Residential instability may also lead to youth in foster care working with multiple
prescribers, which is another risk factor for polypharmacy (Jokanovic et al., 2015; Medhekar et
al., 2019; Rambhade et al., 2012). This could be unintentional; one prescriber may lack
knowledge of what others are prescribing, especially if previous medical records are not
transferred to new prescribers. Contrarily, once a medication is started by a physician, future
prescribers may not discontinue it when transferred care, as new providers less familiar with the
patient may rely on the assumption that the prescribed medication was necessary. Finally,
established medication regimens may be altered to reflect a given prescriber’s preferred
medications for that presenting problem, again resulting in medication changes due to
fluctuations in treatment providers rather than medical need. Overall, there are a multitude of
factors relating to trauma and out-of-home placements that contribute to polypharmacy risk.
Awareness of these factors has led to systems-involved youth in particular being targets of
polypharmacy research and policy (Longhofer et al., 2011).
Justice-Involved Populations
Individuals involved with the criminal justice system are vulnerable to a range of
negative outcomes that may be treated with psychotropic medications, including co-occurring
mental health and substance use disorders, self-harm behaviors, and suicidality (Fazel et al.,
2011; Ogloff et al., 2015). A meta-analysis by Griffiths et al. (2012) investigating psychotropic
drug prescription among persons in prisons noted several important themes. First, offenders are
at high risk for polypharmacy, with insufficient response to monotherapy and concerns about
safety and adherence identified as common justifications for polypharmacy. Polypharmacy was
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also commonly associated with high medication dosages, even at levels exceeding the
recommended daily dose, and medications were often used for lengthy durations of time.
Researchers also highlighted the lack of adherence to prescribing guidelines, particularly those
that recommend monitoring side effects of high-dose medications with many associated ADRs.
Justice-involved youth face similar risks. Psychological disorders are common in juvenile
justice populations, where many youth carry multiple mental health diagnoses (Kang et al., 2018;
Lyons et al., 2013). Common diagnoses include conduct disorder, anxiety disorders, major
depressive disorder, and substance use disorders. Many of these diagnoses can be treated with
psychotropic medications, a method potentially preferred by prescribers if these concerns are
comorbid and are viewed as contributors to aggression or other illegal behaviors. In one study of
youth in state juvenile justice facilities, Lyons and colleagues (2013) noted that although the rate
of psychotropic medication was low, almost half of those receiving any psychotropic medication
were prescribed multiple medications in the 30 days following intake, ranging from 2-5
medications per youth.
Psychotropic medications, namely antipsychotics, are also prescribed more broadly in
youth with behavioral issues commonly associated with delinquency, such as aggression,
impulsivity, irritability, and disruptive behaviors (Blader, 2006; Pringsheim, Panagiotopoulos et
al., 2011; Ninan et al., 2014). Further, increasing numbers of antipsychotics are prescribed offlabel for youth with ADHD to address impulsivity and behavior problems (Pringsheim,
Panagiotopoulos et al., 2011). Several studies note the severity of behavioral problems,
especially aggression, specifically increase the risk for polypharmacy and ADRs (Blader, 2006;
Ninan et al., 2014) in these youth, many of whom come into contact with the justice system due
to problems with aggression and delinquency. Thus, delinquency and justice-system
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involvement, as well as associated externalizing behavioral issues, increase risk for
polypharmacy.
Current Study
Importantly, the symptoms and characteristics of persons in these high-risk groups
associated with polypharmacy often overlap, especially since these risk factors often correlate
with one another. Research illustrates that increasing numbers of ACEs are associated with both
physical and mental health problems (Felitti et al., 1998; Varese et al., 2012), including
externalizing problems that may present as disobedience, inattention, aggression, and substance
abuse (Carliner et al., 2017). These behavior problems may initiate contact with the criminal
justice system. High prevalence rates of trauma, mental health diagnoses, and suicidality are
common amongst justice-involved youth (Björkenstam et al., 2013; Fox et al., 2015; LoganGreene et al., 2017). Further, their behavioral histories are often characterized by aggression and
delinquency, as well as transitions in medical and psychiatric care prompted by child welfare or
justice system involvement.
Adolescents who engage in sexually abusive behavior represent a unique subpopulation
of youth who face a multitude of risks for polypharmacy practices: youthful age, complex
medical and mental health needs, experiences of trauma and out-of-home placements, justice
system involvement, and histories of behavioral problems in a variety of settings. Despite the
connections of polypharmacy to certain characteristics of said youth, no research to date has
examined this population specifically. Some studies have explored prescribing practices for
youth in general residential care, noting the highest rates of polypharmacy for individuals with
behavior problems (Huefner et al., 2017). However, it is unknown if behavior problems that are
sexual in nature pose further risk of polypharmacy. Research also suggests that despite overall
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trends of increasing medications upon admission to a treatment facility, youth whose numbers of
medications decreased were released to less restrictive settings at discharge, indicating a benefit
to medication reconciliation and decreasing polypharmacy when possible (van Wattum et al.,
2013). Given the risk of detrimental outcomes associated with pediatric psychotropic
polypharmacy, in addition to the risks already faced by vulnerable, justice-involved youth,
understanding correlates of polypharmacy in a sample of vulnerable youth may inform future
prevention and intervention strategies to promote optimal care.
The current study will use an existing archival dataset of a sample of adolescents who
have engaged in sexually abusive behaviors to address gaps in the literature and inform effective
treatment practices with this population. Given the high rates of psychiatric comorbidity within
the population and the corresponding risk for between-class comedication, which may lead to
higher risk of ADRs, polypharmacy practices will be examined focusing on specific classes of
psychotropic medications. In addition, the between-class focus will allow for more generalizable
results. The following research aims and corresponding hypotheses will be the focus of this
study:
Research Aim 1
Investigate patterns of psychotropic medication prescription and polypharmacy across different
diagnostic categories, levels of comorbidity, race/ethnicities, and ages.
•

Hypothesis 1a: There may be differential associations between polypharmacy and
participant characteristics by age, race, and type of diagnostic presentation.

•

Hypothesis 1b: Participants with higher levels of comorbidity (i.e., greater numbers of
diagnoses) will evidence higher levels of polypharmacy.
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Research Aim 2
Investigate psychiatric, trauma- and instability-related, and aggressive/criminal variables
associated with polypharmacy in past literature within principal components analysis (PCA) to
understand their relationships with one another, as well as their relationships with psychotropic
medication prescription and polypharmacy.
•

Hypothesis 2a: Conducting PCA as a data reduction technique on the variables of interest
will result in meaningful indices.

•

Hypothesis 2b: Indices derived from the PCA will be associated with the following
outcomes: younger age of initiation of psychotropic medication and higher number of
current drug classes.

•

Hypothesis 2c: Participants with more aggressive/problematic behavioral issues will be
more likely to be prescribed antipsychotic and stimulant/ADHD medications.

Research Aim 3
Explore the impact of admission to residential care on psychotropic prescription practices. Given
that recent hospitalizations, trauma, residential instability, and court involvement are associated
with polypharmacy in the literature, participants may exhibit increases in polypharmacy after
admission to the treatment facility.
•

Hypothesis 3a: Participants will exhibit greater degrees of psychotropic polypharmacy
after admission to the treatment facility, such that they are more likely to have
medications added than subtracted.

•

Hypothesis 3b: Differences in polypharmacy, whether positive or negative, will be
examined based on significant predictors of polypharmacy determined in earlier analyses
involving the PCA indices.
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Chapter 2. Methods
Data Collection & Sample
This study utilized an archival dataset collected from a nonprofit residential treatment
facility for adolescents who have engaged in sexually abusive behaviors. Data collection efforts
were sponsored by funding from the East Tennessee State University Research Development
Committee’s Major Grant program. Data were collected by the primary investigator and trained
undergraduate and graduate research assistants with approval from the East Tennessee State
University Campus Institutional Review Board and the board of directors of the treatment
facility. Data were collected from November 2014 to July of 2017.
Data were obtained from various documents within participants’ records, including:
admission and discharge summaries, psychological testing results, records from the state
Division of Children’s Services (DCS), records from law enforcement, probation, or other
residential placements, court documents, school records, and other treatment evaluations or
records available from the residential facility. Available data varied within each participant’s file
due to differences in length of stay at the facility, county of origin, and medical/psychological
complexity; some participant files yielded more useable data than others.
A total of 295 participants’ files were available for use. The average age at admission to
the treatment facility ranged from 10 to 17, with an average age of 14.80 years old (SD = 1.56).
The majority of participants were male (98.3%, n = 290), and five participants were female.
Eighty-three percent of the sample identified as White/Caucasian (n = 245), followed by African
American/Black (9.5%, n = 28), Multiracial (4.4%, n = 13), Other/Unknown (2.4%, n = 7), and
Hispanic (0.7%, n = 2). Most participants were referred to the treatment facility by DCS (68.5%,
n = 202), followed by court representatives (20.7%, n = 61), mental health providers (4.4%, n =
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13), parents/guardians (3.4%, n = 10), unknown (2%, n = 6), other (0.7%, n = 2), and insurance
representatives (0.3%, n = 1).
Variables
As this study utilized archival data, a total of 44 variables were selected from the precollected dataset that I hypothesized were related to the three domains discussed earlier in this
paper: complex health needs, trauma and instability, and aggressive/criminal behavior. As these
variables would later be entered into the PCA to be reduced, a large number of variables were
selected with the understanding that variables that did not fit well would be removed in later,
iterative steps of the PCA. These variables included specific psychiatric diagnoses, ACEs, details
of out-of-home placements, and data from criminal records. The specific diagnoses included
were ADHD, trauma-related disorders, psychotic disorders, oppositional defiance disorder
(ODD), conduct disorder (CD), and a diagnostic category including intellectual developmental
disorder/autism spectrum/communication (IAC) disorders. Two demographic variables were also
recorded. Finally, a total of nine polypharmacy variables were selected or created as outcome
variables. The presence/absence of six different medication classes were recorded from
participant records. A variable representing the cumulative number of current medication classes
(ranging from zero to six) in use for each participant was calculated. Lastly, a variable
representing the change in cumulative drug classes post-admission to the treatment facility was
created by subtracting the number of previous drug classes prescribed before admission (if
known) from the number of current drug classes being prescribed. Due to the nature of archival
data collection and the possibility of missing data, descriptive analyses were conducted to assess
the frequency of missing data per variable. See Tables 1 and 2 for lists of variables, their coding
mechanisms, descriptive statistics, and missingness.
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Table 1
Independent Variables, Coding Mechanisms, and Descriptive Statistics
Variable
Demographic variables
Race/ethnicity
Age at admission
PCA variables
Total # of diagnoses*

Coded as:
White = 1, non-White = 2
Age in years

ADHD
Trauma-related disorder
Psychotic disorder

Count # of diagnoses, possible values
of 0-21
No = 0, Yes = 1
No = 0, Yes = 1
No = 0, Features = 1, Yes = 2

ODD
Conduct disorder
IDD, autism spectrum, or
communication disorder
Hx of outpatient counseling
Hx of suicide attempts
Hx of suicidal ideation
Age at 1st documented suicidal
ideation
Self-harm bx

No = 0, Yes = 1
No = 0, Yes = 1
None = 0, Yes for at least one disorder
=1
No = 0, Yes = 1
No = 0, Yes = 1
No = 0, Yes = 1
Age in years, 888 if no suicidal
ideation documented
No = 0, Unclear = 1, Yes = 2

# of psychiatric inpatient
admissions
# of out-of-home placements

Count # of admissions
Count # of placements

M (SD),
Range
14.8 (1.6),
10-17
4.1 (2.7),
0-12

12.3 (3.1),
4-17
1.0 (1.8),
0-13
5.5 (6.4),
0-64

n (%)
245 (83.1%) White

Missing data
n (%)
0
1.0%
3 (1.0%)

209 (70.8%)
71 (24.1%)
18 (6.1%) Yes,
15 (5.1%) w/ features
91 (30.8%)
102 (34.6%)
87 (29.5%)

4 (1.4%)
12 (4.1%)
10 (3.4%)

261 (88.5%)
68 (23.1%)
131 (44.4%)

7 (2.4%)
11 (3.7%)
9 (3.1%)
42 (14.2%)

107 (36.3%) Yes, 16
(5.4%) Unclear intent

9 (3.1%)

10 (3.4%)
8 (2.7%)
8 (2.7%)

5 (1.7%)
1 (0.3%)

Duration in out-of-home
placements
# of schools attended

# of years in placements prior to
admission
Count # of schools attended

ACEs: Physical abuse
Emotional abuse
Sexual abuse
Emotional neglect
Physical/medical neglect
Parental divorce
Domestic violence
Caregiver substance use
Caregiver mental illness
Caregiver incarceration
# of arrests

No = 0, Yes = 1
No = 0, Yes = 1
No = 0, Yes = 1
No = 0, Yes = 1
No = 0, Yes = 1
No = 0, Yes = 1
No = 0, Yes = 1
No = 0, Yes = 1
No = 0, Yes = 1
No = 0, Yes = 1
Count # of arrests

Duration of time incarcerated

# of years; "Brief" or unspecified =
0.5, 0-4 months = 0.3, 5-8 months =
0.6, 9-12 months = 1
Age in years, 888 if never arrested

Age at 1st arrest
Hx of aggression
Age at 1st aggressive bx
Hx of animal cruelty
Hx of impulsivity
Hx of anger dyscontrol (e.g.,
temper tantrums)
# of nonsexual violent arrests
Placements d/t bx problems
Hx of behavioral problems at
school

No = 0, Yes = 1
Age in years, 888 if no hx of
aggression
No = 0, Yes = 1
No = 0, Yes = 1
No = 0, Yes = 1

3.4 (3.9),
0-16
5.0 (3.5),
1-30

2.1 (2.6),
0-14
0.1 (0.3),
0-2
13.3 (1.9),
7-17
9.1 (3.8),
2-17

Count # of arrests

0.4 (0.9),
0-8

No = 0, Yes = 1
No = 0, Yes = 1
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23 (7.8%)
45 (15.3%)
151 (51.2%)
109 (36.9%)
182 (61.7%)
86 (29.2%)
113 (38.3%)
247 (83.7%)
121 (41.0%)
190 (64.4%)
137 (46.4%)
122 (41.4%)

0
0
0
0
0
0
0
0
0
0
6 (2.0%)
23 (7.8%)
11 (3.7%)

258 (87.5%)

8 (2.7%)
108 (36.6%)

94 (31.9%)
106 (35.9%)
130 (44.1%)

11 (3.7%)
13 (4.4%)
11 (3.7%)
8 (2.7%)

116 (39.3%)
235 (79.7%)

13 (4.4%)
11 (3.7%)

Violent bx at school
Sexual bx at school
Sexual offenses & behaviors:
Adult contact victims
Child contact victims
Violent 1st sexual offense
Age at 1st sexual offense

No = 0, Yes = 1
No = 0, Yes = 1

166 (56.3%)
83 (28.1%)

15 (5.1%)
15 (5.1%)

No = 0, Yes = 1
No = 0, Yes = 1
No = 0, Yes = 1
Age in years, 888 if no sexual offense

18 (6.1%)
257 (87.1%)
30 (10.2%)

10 (3.4%)
10 (3.4%)
22 (7.5%)
16 (5.4%)

11.7 (2.9),
4-17

Placements d/t inappropriate
No = 0, Yes = 1
195 (66.1%)
13 (4.4%)
sexual bx
Note. Bx =behavior, hx = history. Child contact victims and adult contact victims not mutually exclusive, as some participants may
have both. *21 diagnoses include: Intellectual or developmental disability, Specific learning disorder, Autism spectrum disorder,
Communication disorder, Motor disorder, Elimination disorder, Feeding disorder, Sleep disorder, Reactive attachment disorder,
Attention-deficit/hyperactivity disorder, Mood disorder, Anxiety disorder, Obsessive-compulsive or related disorder, Psychotic
disorder, Adjustment disorder, Trauma-related disorder, Oppositional defiant disorder, Conduct disorder, Intermittent explosive
disorder, Other impulse control disorder, and Substance abuse disorder.
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Table 2
Dependent Variables, Coding Mechanisms, and Descriptive Statistics
Dependent Variable

Coded as:

M (SD), Range

Psych Medication Age

Age in years that client began
taking psychotropic meds, 888 if no
hx of psych meds

7.9 (4.0), 0-16

n (%)

Missing data
n (%)
131 (44.4%)

Current Medications: Drug Classes
1. Antidepressants

No = 0, Yes = 1

156 (52.9%)

12 (4.1%)

2. Mood stabilizers

No = 0, Yes = 1

145 (49.2%)

12 (4.1%)

3. Antipsychotics

No = 0, Yes = 1

114 (38.6%)

12 (4.1%)

4. Anxiety medications

No = 0, Yes = 1

155 (52.5%)

12 (4.1%)

5. Stimulants/ADHD medications

No = 0, Yes = 1

110 (37.3%)

12 (4.1%)

6. Medications for side effects

No = 0, Yes = 1

14 (4.7%)

12 (4.1%)

Cumulative classes including side
effect medications

Count # of current drug classes

Change in cumulative classes, past vs.
current medications

Difference between past cumulative
classes & current cumulative
classes, possible values of -6 to +6
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2.5 (1.9), 0-6

12 (4.1%)

.40 (1.7),
-5 to +5

17 (5.8%)

Data Analytic Plan
My objective is to better understand how various factors relate to different measurements
of psychotropic medication use and polypharmacy. Specific hypotheses and exploratory aims are
discussed below. The predicted hypotheses were pre-registered and time stamped on the Open
Science Framework web server. The following study design was also pre-planned and included
on the study’s preregistration, which can be found at the following link: https://osf.io/wxs5r/.
Analyses were conducted in IBM SPSS Statistics version 26.23.1. For group differences (t-tests
and χ2), data were excluded listwise. For regression analyses, data were excluded pairwise. The
standard p < .05 criteria for a two-tailed test was utilized for determining significance. Outliers
were not excluded from the analyses.
Research Aim 1
Hypothesis 1a: There may be differential associations between polypharmacy and
participant characteristics by age, race, and type of diagnostic presentation. Exploratory
analyses were conducted to examine relationships between polypharmacy practices, age, and
race/ethnicity. Due to the majority of participants being White, race/ethnicity was recoded as
White (coded as 1) and non-White (coded as 2).
A linear regression analysis was conducted to examine the effect of age at admission and
number of medication classes prescribed. Independent samples t-tests were conducted to test for
significant differences between the number of medication classes prescribed for White and NonWhite participants. χ2 analyses were completed for each medication class and racial group
(White versus non-White). For each specific diagnostic category (ADHD, trauma-related
disorder, psychotic disorder, ODD, CD, and IAC disorders), the following were conducted: 1)
descriptive statistics for the mean number of medication classes prescribed for participants with

that diagnosis, 2) the percentage of participants with that diagnosis that were prescribed each
medication class, 3) t-tests and χ2 analyses to examine if these polypharmacy variables were
significantly different in participants with the diagnosis compared to those without the diagnosis.
Note that for this hypothesis only, the psychotic disorder diagnosis variable was dichotomized,
such that participants with features of psychosis were grouped together with those with a formal
psychotic disorder diagnosis.
Hypothesis 1b: Participants with higher levels of comorbidity (i.e., greater numbers of
diagnoses) will evidence higher levels of polypharmacy. Linear regression analyses were
conducted to examine if a significant relationship exists between number of cumulative
diagnoses and two polypharmacy variables: younger age of initiation of psychotropic medication
and number of current drug classes prescribed.
Research Aim 2
As there are many potential independent variables that can inform polypharmacy in this
population, I first used Principal Component Analysis (PCA), a data reduction technique
designed to create one or more index variables from a larger set of measured variables. This
analysis will help illustrate how the individual variables correlate with one another, resulting in
components or indices that can be entered into later regression analyses as independent variables.
The aim of the PCA is to simplify the statistical analyses to achieve more meaningful results and
to account for collinearity amongst individual predictor variables.
Hypothesis 2a: Conducting PCA as a data reduction technique on the variables of
interest will result in meaningful indices. For the first step, the 44 independent variables were
entered into the PCA. No rotation was utilized in this step to best represent true patterns and
associated correlations within the data. The corresponding scree plot and Eigenvalues were
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examined to help determine which component structure might fit the data best. Further steps of
the PCA were conducted using an iterative approach to reduce the data to best fit the proposed
components, utilizing the Oblimin with Kaiser Normalization rotation for each subsequent PCA.
This rotation is appropriate for oblique components, as it was expected that components could be
correlated with one another (Kahn, 2006). A cutoff of 0.40 for structure coefficients was selected
for inclusion of variables into the components. To eliminate variables that did not fit well into
any components, a cutoff of 0.30 for all components was utilized as a threshold. That is,
variables that did not load on any components at 0.30 or above following the second iteration of
PCA were removed before continuing the iterative process of further PCAs. Imputation of means
for missing data was utilized in all steps of the PCA as few variables yielded notable amounts of
missingness (see Table 1).
Hypothesis 2b: Indices derived from the PCA will be associated with the following
outcomes: younger age of initiation of psychotropic medication and higher number of current
drug classes; participants with more aggressive/problematic behavioral issues will be more
likely to be prescribed antipsychotic and stimulant/ADHD medications. These hypotheses were
exploratory and dependent upon the results of the PCA. After a PCA model with appropriate fit
was determined, factor scores were computed using the Thurstone least squares regression
method, which predicts the location of each individual on the component and allows for the
components to be used as independent variables in further regression analyses (Distefano, Zhu,
& Mindrila, 2008). The factor scores were input as independent variables in separate multiple
regression analyses for two dependent variables: age of initiation of psychotropic medication and
number of current drug classes.
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Hypothesis 2c: Participants with more aggressive/problematic behavioral issues will be
more likely to be prescribed antipsychotic and stimulant/ADHD medications. The
aforementioned factor scores were also input as independent variables in separate logistic
regression analyses for two dependent variables: current antipsychotic medications and current
stimulant/ADHD medications.
Research Aim 3
Hypothesis 3a: Participants will exhibit greater degrees of psychotropic polypharmacy
after admission to the treatment facility, such that they are more likely to have medications
added than subtracted. Descriptive statistics of the change variable that subtracts the number of
previous drug classes prescribed from the number of current drug classes prescribed were
analyzed, and a histogram was created to visually represent this data.
Hypothesis 3b: Differences in polypharmacy, whether positive or negative, will be
examined based on significant predictors of polypharmacy determined in earlier analyses. Two
regressions were conducted with the change variable as the dependent variable: one with number
of diagnoses as the independent variable, and one with the PCA components as independent
variables.
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Chapter 3. Results
Descriptive statistics of each variable can be found in Tables 1 and 2. Psychiatric
concerns and diagnoses were prevalent in the sample. The average number of diagnoses was 4.1,
and the maximum number was 12. Regarding specific diagnoses, the most common was ADHD
(70.8%), followed by conduct disorder (34.6%), ODD (30.8%), IAC disorders (29.5%), traumarelated disorders (24.1%), and psychotic disorders (6.1%). A large majority of participants
(88.5%) had received previous outpatient counseling. Notably, elevated rates of suicidality were
evidenced in the sample, with almost half (44.4%) of participants having a history of suicidal
ideation and 19% of participants having a history of suicide attempts.
Indicators of instability and trauma were also common. The average number of out-ofhome placements was 5.5, and the maximum number was 64. The average duration of time in
out-of-home placements was 3.4 years, with maximum of 16 years. On average, participants
attended five different schools; one participant attended 30 schools. ACEs were common, with
the most prevalent ACEs being parental divorce, caregiver substance abuse, sexual abuse, and
physical abuse. All four of these ACEs occurred in over half of the sample.
Many of the participants’ histories were characterized by behavioral problems. A large
majority of participants evidenced a history of aggression (87.5%). Prevalence rates of anger
dyscontrol (44.1%), impulsivity (35.9%), and animal cruelty (31.9%) were also notable. Many
participants exhibited behavioral problems at both home and school. The average number of
arrests was 2.1, though duration of incarceration rates were low (M = 0.1 years). Most
participants had sexual crimes with child contact victims (87.1%), but very few had adult contact
victims (6.1%).
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With regard to polypharmacy, the average age of initiation of psychotropic medications
was 7.9 years, though several participants began taking psychotropic medications before the age
of one. Antidepressant (52.9%), anxiety (52.5%), and mood stabilizer (49.2%) medications were
most common, though antipsychotics (38.6%) and ADHD/stimulant medications (37.3%) were
also prevalent. Few participants (4.7%) were prescribed medications for side effects. The
average number of medication classes currently prescribed was 2.5, with almost one-fifth of
participants prescribed five or six medication classes.
Due to the nature of archival data collection from historical records, missing data is
possible, as records may lack details from prior years, especially for participants with
particularly unstable lives or those who experienced maltreatment at very young ages. Four
variables had notable amounts of missing data (>10%): age at first aggressive behavior (36.6%),
number of schools attended (15.3%), age at first documented suicidal ideation (14.2%), and age
of initiation of psychotropic medication (44.4%). It is important to note the significant amount of
missingness for age of initiation of psychotropic medication, as analyses with this dependent
variable will yield smaller sample sizes that may limit statistical power.
Research Aim 1
Hypothesis 1a: There may be differential associations between polypharmacy and
participant characteristics by age, race, and type of diagnostic presentation. Multiple regression
analysis was used to test the ability of age at admission to significantly predict the cumulative
number of medication classes currently prescribed (see Table 3). The results of the regression
indicated that age was not a significant predictor, and the overall model was not significant.
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Table 3
Regression Analysis Summary for Age at Admission Predicting Number of Medication Classes (n
= 282)
Variable

B

SE B

(Intercept)

1.67

1.06

Age at admission

.05

.07

β
.04

t

p

1.58

.12

.74

.46

Note. R2 = .00, F=.55

An independent samples t-test was conducted to examine group differences in cumulative
number of medication classes currently prescribed based on participant race. There was no
significant effect for race, t(281) = 1.49, p = .08, despite White participants (n = 239, M =
2.52, SD = 1.83) being prescribed more medication classes on average than non-White
participants (n =44, M = 2.07, SD = 2.03). Regarding specific medication classes, there was a
significant association between race and current antidepressant medications (χ2(1) = 5.73, p <
.05), such that White participants were more likely to be prescribed antidepressants. No
associations were found between race and current mood stabilizer (χ 2(1)> = .70, p = 0.10),
antipsychotic (χ 2(1)> = .06, p = 0.81), anxiety (χ2(1)> = 2.82, p = 0.09), stimulant (χ 2(1)> =
0.09, p = 0.76), or side effect (χ 2(1)> = 2.71, p = 0.10) medications.
Table 4 summarizes the findings of analyses specific to each diagnostic category, with
significance denoted for t-test and χ2 comparisons between individuals with or without each
diagnosis. Note that the diagnostic categories are not mutually exclusive across the entire
sample, as some participants have multiple diagnoses. The diagnostic categories with the highest
mean numbers of medication classes were psychotic disorders (M = 3.97), trauma-related
disorders (M = 3.55), and IAC disorders (M = 3.13). Antidepressants were most commonly
prescribed for trauma-related disorders (82%) and psychotic disorders (88%), though all
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diagnostic categories exhibited prevalence rates of individuals prescribed antidepressants higher
than 60%. A similar trend emerged for mood stabilizer medications. Anxiety medications were
most prevalent for psychotic disorders (84%) and trauma-related disorders (75%).
Antipsychotics were prescribed for about half of participants with ADHD, CD, and ODD, while
rates of antipsychotic prescription were upwards of 60% for the diagnostic categories of traumarelated disorders, psychotic disorders, and IAC disorders. About half of individuals in each
diagnostic category were prescribed ADHD medications/stimulants. Prevalence rates of
medications for side effects were low except for those with psychotic disorders, for whom nearly
20% were prescribed such medications.

Table 4
Descriptive Statistics of Polypharmacy Variables by Diagnostic Category
Diagnostic
category

# of med classes
M (SD)

Antidepressants

Mood
stabilizers

Antipsychotics

Anxiety
meds

ADHD meds/
stimulants

Meds for
side effects

ADHD
(n=202)

2.96
(1.73)

63.37%**

60.89%**

49.01%**

63.37%**

53.96**

.05%

Trauma-related
(n=71)

3.55**
(1.49)

81.69%**

77.46%**

61.97%**

74.65%**

49.30%*

9.86%*

Psychotic
(n=32)

3.97**
(1.31)

87.50%**

78.13%**

68.75%**

84.38%**

59.38%**

18.75%**

ODD
(n=87)

2.94
(1.84)

64.37%*

63.22%**

49.43%*

60.92%

50.57%**

5.75%

CD
(n=97)

2.98**
(1.78)

64.95%*

63.92%**

49.48%*

64.95%**

47.42%*

7.22%

IAC disorder
(n=87)

3.13**
(1.74)

62.07%

70.11%**

62.07%**

63.22%

45.98%

9.20%*

Note. ADHD = attention-deficit/hyperactivity disorder, ODD = oppositional defiant disorder, CD = conduct disorder, IAC =
intellectual developmental disability/autism spectrum/communication disorder, meds = medications.
*p < .05, **p < .01. Significance levels indicate the presence or absence of significant differences between participants with and
without the disorder resulting from t-tests and χ2 analyses.

Hypothesis 1b: Participants with higher levels of comorbidity (i.e., greater numbers of
diagnoses) will evidence higher levels of polypharmacy. Multiple regression analysis was used to
test if number of diagnoses significantly predicted the age of initiation of psychotropic
medication (see Table 5). The results of the regression indicated that number of diagnoses was
not a significant predictor, and the overall model was not significant.
Table 5
Regression Analysis Summary for Number of Diagnoses Predicting Age of Initiation of
Psychotropic Medications (n=118)
Variable

B

SE B

(Intercept)

8.20

.69

Number of diagnoses

-.08

.14

β
-.05

t

p

11.93

.00**

-.55

.58

Note. R2 = .00, F=.31, **p < .01

A second multiple regression analysis was conducted to test if number of diagnoses significantly
predicted the number of medication classes currently in use (see Table 6). The results of the
regression indicated number of diagnoses significantly predicted number of current medication
classes (β = .38, p < .001), explaining 28.5% of the variance (R2 = .29, F(1,281) = 113.62, p <
.001).
Table 6
Regression Analysis Summary for Number of Diagnoses Predicting Number of Medication
Classes (n = 283)
Variable

B

SE B

(Intercept)

.90

.17

Number of diagnoses

.38

.04

β
.54

Note. R2 = .29, F=113.62**, **p < .01
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t

p

5.16

.00**

10.66

.00**

Research Aim 2
Hypothesis 2a: Conducting PCA as a data reduction technique on the variables of
interest will result in meaningful indices. The initial step of the PCA included all 44 variables of
interest, and no rotation was utilized (see Figure 1).
Figure 1
Scree Plot of the First Iteration of Principal Component Analysis

Kaiser’s criterion (i.e., retaining the number of factors with Eigenvalues greater than one)
suggested a 15-component solution. Examining the scree plot visually (i.e., “scree test”)
suggested a four-component solution. The second iteration of PCA included all 44 variables of
interest and utilized the Oblimin with Kaiser Normalization rotation. Given the results of the
scree test, a four-component solution was examined. The four-component solution explained
30.32% of the variance. After examining the pattern matrix, seven variables did not meet the
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0.30 loading threshold for any of the components: age at first suicidal ideation, number of
schools attended, history of animal cruelty, age at first sexual offense, violent first sexual
offense, adult contact victims, and placements due to history of inappropriate sexual behaviors.
Thirteen of the remaining 37 variables yielded loadings higher than the 0.30 inclusion threshold
but did not load at 0.40 or above on any of the resulting components. These, however, were
retained, as they did evidence some degree of relationship with the components. The fourcomponent solution PCA was run again after removing the seven variables that did not meet the
inclusion threshold.
The resulting four-component solution explained 34.51% of the variance, and all 37
variables met the 0.30 inclusion threshold. Eleven variables did not load at 0.40 or above on any
of the components, though each of these loaded at 0.30 or above on a single component,
suggesting some level of concordance with the variables associated with that component. Other
alternative models were tested, including a three-component solution, but the final fourcomponent model was retained. See Tables 7 and 8 for the pattern matrix of the final solution
and component correlation matrix.
Table 7
Pattern Matrix of Final Solution of Principal Components Analysis
Variable
Component 1: Psychiatric
concerns

1

# of inpatient admissions

.661

Hx of suicide attempts

.590

Hx of suicidal ideation

.613

Hx of self-harm bx

.600

Cumulative # of diagnoses

.751

Component
2
3

43

4

Variance
Explained
17.17%

ADHD

.458

Psychotic disorder

.440

Trauma-related disorder

.504

IAC disorder

.402

ODD

.374

Conduct disorder

.326

# of out-of-home placements

.522

Placements d/t bx problems

.446

Age at 1st aggressive bx

-.366

Hx of impulsivity

.336

Hx of anger dyscontrol

.376

.301

Component 2: ACEs

6.52%

Emotional abuse

.580

Physical abuse

.640

Sexual abuse

.393

Emotional neglect

.678

-.344

Physical/medical neglect

.685

-.340

Parental divorce

.453

Domestic violence

.643

Caregiver substance use

.555

Caregiver mental illness

.408

Caregiver incarceration

.463

Duration in out-of-home
placements

.303

Component 3: Justice-system
involvement

5.73%

# of arrests

.823

Age at 1st arrest

-.442

# nonsexual violent arrests

.691

Duration of time incarcerated

.335

Component 4: Aggression &
behavioral problems

5.09%
.423

Hx aggression
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Bx problems at school

.314

.608

Violent bx at school

.350

.535

Sexual bx at school

.316

Child contact victims

.343

Hx of outpatient counseling

.367

Note. ADHD = attention-deficit/hyperactivity disorder, bx = behavior, d/t = due to, hx = history,
IAC = intellectual developmental disability/autism spectrum/communication disorder, ODD =
oppositional defiant disorder. The extraction method was principal component with an oblique
(Oblimin with Kaiser Normalization) rotation. Factor loadings above .40 are in bold.
Table 8
Component Correlation Matrix of Four-Component Solution
Component

1

2

3

2

.259

-

3

.107

.104

-

4

.057

.087

-.024

4

-

Component 1 contained variables primarily associated with psychiatric symptoms,
including diagnoses, suicidality, and inpatient admissions. Component 1 also included variables
relating to aggression and behavioral problems (i.e., impulsivity, anger dyscontrol, and
behavioral problems), which are often symptoms of psychiatric diagnoses. Additionally,
Component 1 included two variables related to out-of-home placements: number of placements
and placements due to behavioral problems. Component 2 contained the ACE variables and the
duration of out-of-home placements. Component 3 contained variables directly related to
criminal justice system involvement, including arrests and incarceration. Component 4 included
variables relating to behavioral problems and aggression, as well as outpatient counseling and
child contact victims.

45

Hypothesis 2b: Indices derived from the PCA will be associated with the following
outcomes: younger age of initiation of psychotropic medication and higher number of current
drug classes. Multiple regression analysis was conducted to examine if the four components
from the PCA significantly predicted the age of initiation of psychotropic medication (see Table
9). The results of the regression indicated no significant predictors, and the overall model was
not significant.
Table 9
Regression Analysis Summary for PCA Components Predicting Age of Initiation of Psychotropic
Medication (n=118)
Variable

B

SE B

(Intercept)

7.88

.37

C1: Psychiatric concerns

-.49

.39

C2: ACEs

-.05

C3: Justice-system
involvement
C4: Aggression &
behavioral problems

β

t

p

21.14

.00**

-.12

-1.25

.21

.39

-.01

-.13

.89

.02

.38

.00

.04

.97

-.05

.38

-.01

-.14

.89

Note. R2 = .02, F=.46, **p < .01

A second multiple regression analysis was conducted to examine if the four components
significantly predicted the number of medication classes currently in use (see Table 10). The
results of the regression indicated Component 1: Psychiatric concerns (β = 1.00, p < .001) and
Component 2: ACEs (β = .30, p < .01) were significant predictors, and the overall model was
significant (R2 = .39, F(4,278) = 43.50, p < .001).
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Table 10
Regression Analysis Summary for PCA Components Predicting Number of Medication Classes
(n=283)
Variable

B

SE B

(Intercept)

2.45

.09

C1: Psychiatric concerns

1.00

.09

C2: ACEs

.30

C3: Justice-system
involvement
C4: Aggression &
behavioral problems

β

t

p

28.02

.00**

.54

10.99

.00**

.09

.16

3.30

.00**

.15

.09

.08

1.64

.10

.10

.09

.05

1.13

.26

Note. R2 = .39, F=43.50**, **p < .01

Hypothesis 2c: Participants with more aggressive/problematic behavioral issues will be
more likely to be prescribed antipsychotic and stimulant/ADHD medications. A logistic
regression was performed to ascertain the effects of each component from the PCA on the
likelihood that participants are prescribed antipsychotic medications (see Table 11). The model
was statistically significant and accounted for 33% (Nagelkerke R2) of the variance. Component
1: Psychiatric concerns and Component 2: ACEs were significant predictors, such that increasing
scores on such components were associated with an increased likelihood of being prescribed
antipsychotic medications.
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Table 11
Regression Analysis Summary for PCA Components Predicting Antipsychotic Medications (n =
283)
B

SE

Wald

df

p

Exp(B)

95% CI for
EXP(B)

C1: Psychiatric
concerns

1.00

.16

38.22

1

.00**

2.71

1.98-3.72

C2: ACEs

.52

.15

11.83

1

.00**

1.68

1.25-2.25

C3: Justice-system
involvement

.23

.14

2.51

1

.11

1.25

.95-1.66

C4: Aggression &
behavioral problems

.15

.15

1.01

1

.32

1.16

.87-1.56

(Constant)

-.54

.15

13.58

1

.00**

.59

Variable

Note. -2LL(df) = 301.06(4)**, Nagelkerke R2 = .33, **p <.01
A second logistic regression was performed to ascertain the effects of each component
from the PCA on the likelihood that participants are prescribed ADHD/stimulant medications
(see Table 12). The model was statistically significant and accounted for 15% (Nagelkerke R2) of
the variance. Component 1: Psychiatric concerns and Component 3: Justice-system involvement
were significant predictors, such that increasing scores on such components were associated with
an increased likelihood of being prescribed ADHD/stimulant medications.
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Table 12
Regression Analysis Summary for PCA Components Predicting ADHD/Stimulant Medications (n
= 283)
B

SE

Wald

df

p

Exp(B)

95% CI for
EXP(B)

C1: Psychiatric
concerns

.55

.14

16.06

1

.00**

1.73

1.32-2.26

C2: ACEs

.25

.14

3.41

1

.07

1.29

.99-1.68

C3: Justice-system
involvement

.28

.13

4.32

1

.04*

1.32

1.02-1.71

C4: Aggression &
behavioral problems

.07

.14

.24

1

.62

1.07

.82-1.39

(Constant)

-.51

.13

15.23

1

.00**

.60

Variable

Note. -2LL(df) = 344.81(4)**, Nagelkerke R2 = .15, *p < .05, **p < .01
Research Aim 3
Hypothesis 3a: Participants will exhibit greater degrees of psychotropic polypharmacy
after admission to the treatment facility, such that they are more likely to have medications
added than subtracted. The frequencies in values of the change variable calculated are listed in
Table 13, and a histogram of this data is provided in Figure 2. Although 37.8% (n = 105) of
participants did not experience a change in the number of medication classes prescribed
following admission to the treatment facility, 38.9% (n = 108) experienced an increase and
23.5% (n = 65) experienced a decrease. Few participants experienced a large change in the
number of classes prescribed after admission, with most participants falling in the -2 to +3 range.
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Table 13
Frequencies of Variable Representing Change in Number of Medication Classes Prescribed
After Admission to Treatment Facility (n = 278)
Frequency Percent
-5
1
.4
-4
6
2.2
-3
6
2.2
-2
17
6.1
-1
35
12.6
0
105
37.8
1
40
14.4
2
30
10.8
3
29
10.4
4
6
2.2
5
3
1.1
Total
278
100.0
Figure 2
Histogram Representing the Change in Number of Medication Classes After Admission to the
Treatment Facility
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Hypothesis 3b: Differences in polypharmacy, whether positive or negative, will be
examined based on significant predictor indices of polypharmacy determined in earlier analyses.
Two regressions were conducted with the change variable as the dependent variable: one with
number of diagnoses as the independent variable, and one with the PCA components as
independent variables (see Tables 14 & 15). Neither model was significant, and neither produced
significant predictors.
Table 14
Regression Analysis Summary for Number of Diagnoses Predicting Change in Medication
Classes Post-Admission (n = 278)
Variable

B

SE B

(Intercept)

.49

.19

Number of diagnoses

-.02

.04

β
-.03

t

p

2.53

.01*

-.56

.57

Note. R2 = .00, F=.32, *p < .05
Table 15
Regression Analysis Summary for PCA Components Predicting Change in Medication Classes
Post-Admission (n = 278)
Variable

B

SE B

(Intercept)

.40

.10

C1: Psychiatric concerns

-.09

.12

C2: ACEs

.19

C3: Justice-system involvement
C4: Aggression & behavioral
problems

β

t

p

3.82

.00**

-.05

-.86

.39

.11

.11

1.79

.08

-.12

.11

-.07

-1.12

.27

-.07

.10

-.04

-.66

.51

Note. R2 = .02, F=1.18, **p < .01
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Chapter 4. Discussion
This study is the first to examine polypharmacy specific to adolescents who have
engaged in sexually abusive behaviors. Though past literature suggests this population is at risk
for polypharmacy given characteristics of such youth, prescribing practices may be different than
for those in related groups. Additionally, this study sought to examine what factors might be
most relevant to the practice of polypharmacy in this population.
Descriptive results were consistent with prior research in that the sample evidenced
elevated rates of ACEs, indicators of residential instability, psychiatric concerns, and behavior
problems. Previous studies have evidenced skewed distribution rates of ACEs in adolescents
who have engaged in sexually abusive behaviors, with few youth experiencing low numbers of
ACEs and the majority of youth experiencing four or more ACEs (Barra et al., 2017; Hall et al.,
2017). Results indicate our sample not only evidences high rates of overt abuse (e.g., 61% of
youth were sexually abused, and 51% were physically abused), but also household dysfunction.
Over 80% of participants experienced parental separation/divorce, and prevalence of other
indicators of household dysfunction were in excess of 40%. The high prevalence of ACEs in this
sample is likely associated with DCS involvement and movement to various residential
placements. High numbers of out-of-home placements and multiple schools in the current sample
illustrate the level of inconsistency and uncertainty in these adolescents’ lives. Each movement
also represents a possible disruption in medical or psychological care, contributing to the risk of
polypharmacy.
Also consistent with past literature involving justice-involved youth is the high rate of
comorbid psychiatric diagnoses, as well as more serious psychiatric concerns such as suicidality
and self-harm (Fazel et al., 2011; Ogloff et al., 2015). Notably, the rate of previous suicide
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attempts for this sample is 23%, which is more than double the estimated rates for adolescents in
the community, which typically range from 5-10% (Kann et al., 2014). A higher level of acuity
and severity is indicated for such concerns, which puts individuals at further risk for
polypharmacy (Brenner et al., 2014; Fontanella et al., 2009). Behavior problems were also
common, which is notable as these issues are often treated pharmacologically, especially with
medications with more severe side effects (e.g., antipsychotics and stimulants; Blader, 2006;
Ninan et al., 2014). Overall, descriptive findings corroborate that the current sample is a subset
of different groups at higher risk for polypharmacy.
General Trends in Prescribing
Many participants began taking psychotropic medications at a young age, with some
being prescribed such medications as infants. Notably, 17% of participants (inclusive of those for
whom no medication was prescribed or who had missing data; otherwise, 44% of those for
whom medications were used) initiated psychotropic medications at or before age six, which is
the age range that researchers caution against prescribing for given the risks for altering child
development and possible chronic use of such medications (Crismon & Argo, 2009). Almost
20% of the current sample falling in this category is concerning, as there are high risks of lasting
impacts on neurodevelopment and concerns of ADRs for individuals this young. These children
are less able, or not able at all, to communicate about ADRs or general mood while on such
medications. This finding clearly illustrates that prescribing decisions do not always follow
published guidelines, which should be of public concern.
The current findings confirmed suspected high rates of polypharmacy in this sample.
Over 67% of the sample were prescribed medications from two or more classes. Antidepressants
and anti-anxiety medications were the most commonly prescribed classes, but classes known for
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more extreme ADRs were not uncommon. The high prevalence of antipsychotics (38% overall)
is concerning, especially considering that few participants (6.1%) were diagnosed with a
psychotic disorder. This high rate of antipsychotic prescription is consistent with other research
suggesting that antipsychotics are often prescribed off-label to individuals with behavior
problems (Pringsheim, Panagiotopoulos et al., 2011), as most participants evidenced aggression
and behavioral issues in various settings. Specific diagnostic categories with high prevalence of
antipsychotics included ODD and CD (>50%), as well as IAC disorders and trauma-related
disorders (<60%). This may be related to behavioral issues as well, given that those with IAC
disorders often evidence irritability, difficulty with communication, and low frustration
tolerance, all of which could present as externalizing problems. Research investigating off-label
prescribing of antipsychotics denotes rising use among youth with autism spectrum disorders to
treat such behaviors (Pringsheim, Panagiotopoulos et al., 2011; Malone et al., 2007).
Additionally, symptoms of post-traumatic stress may be misinterpreted as inattention or
hyperactivity (Hodas, 2006).
Given that antipsychotics often cause sedating and deactivating side effects in children,
an ethical question arises as to how and why these medications are beneficial to the presenting
problem of behavioral issues. The associated deactivation provides a rapid treatment alternative
to address behavior issues in comparison to behavioral therapies, which may take more time and
effort to implement. However, psychosocial and behavioral therapies remain the frontline
treatment for aggression and behavior management. It is suggested that these therapies be
implemented continuously even if medications are introduced, as the former have robust
empirical evidence for long-term outcomes and can also address other areas of the youth’s life,
such as caregiver attachment and communication (Magalotti et al., 2019). Because antipsychotic
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medications are known for potentially severe metabolic and neurological ADRs, extreme caution
should be utilized when prescribed to youth, and sufficient monitoring for ADRs is necessary
(Pringsheim, Doja et al., 2011). Psychosocial therapies may be more ethically appropriate for
treating these issues, with pharmalogical interventions utilized temporarily when necessary.
The prevalence rate of medications for side effects was surprisingly low (i.e., 4.7%
overall) given the degree of polypharmacy and high prevalence of antipsychotics in this sample.
However, this could represent differences in dosing, physical health, and response to medication
in younger people as opposed to psychiatric adult populations, where medications for side effects
are much more common (Stroup & Gray, 2018). The low rate in this sample could perhaps be
viewed as positive, as concomitant medications, though sometimes necessary, are typically
considered undesirable unless other management strategies have failed (Stroup & Gray, 2018).
The current study did reveal a positive association between cumulative diagnoses and
number of medication classes prescribed, though this was not true for age of initiation of
psychotropic medications. These results support the strong link between comorbidity and
polypharmacy evidenced in other studies (e.g., Comer et al., 2010; Duffy et al., 2005).
Demographic factors did not significantly impact polypharmacy practices, except that
antidepressants were more common for White participants. Diagnostic categories with the
highest averages of medication classes were psychotic spectrum disorders, trauma-related
disorders, and IAC disorders, which may be illustrative of diagnoses with more acuity, severity,
or treatment-interfering behaviors being at greater risk for polypharmacy.
Principal Component Analysis
The exploratory PCA was conducted in hopes of better understanding how these risk
factors for polypharmacy may interact with one another. Past research has examined subsets of
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the variables selected, though a more detailed analysis of a larger number of risk factors was
conducted to determine patterns and groupings of such variables within this unique population.
The analysis yielded four components that were named in accordance with the variables they
include. Notably, variables that represented behavioral problems dispersed across the
components, suggesting nuanced relationships with other variables within those components.
Impulsivity, anger dyscontrol, age at first aggressive behavior, and out-of-home placements due
to behavior problems loaded on Component 1: Psychiatric concerns, while other aggression- and
behavior-related variables loaded on Component 4: Aggression & behavioral problems. This is
likely due to the fact that behavior issues can be direct symptoms of psychiatric diagnoses, such
as ADHD, ODD, CD, or IAC disorders. However, it is an interesting finding that similar
variables grouped across differing components. Additionally, variables relating to out-of-home
placements were found in both Component 1: Psychiatric concerns and Component 2: ACEs.
Typically, residential placements are preceded by trauma and DCS involvement, but placements
due to behavior problems and total number of placements grouped with the psychiatric variables.
This could indicate that participants with more placements evidenced greater behavioral
problems and psychiatric concerns. Contents of Component 1 indicate that behavioral problems
are common for those with complex psychiatric needs, and such behavioral problems could
initiate a transition in placements.
Though it might be assumed that youth with severe behavioral problems would be more
likely to contact the criminal justice system, results from the PCA indicated that Component 3:
Justice-system involvement and Component 4: Aggression & behavioral problems were not
highly correlated. Thus, there may be a distinction between informal aggressive behaviors and
aggression/violence that justifies formal criminal charges. This may also reflect efforts at
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diversion or other mechanisms intended to redirect youth with histories of aggression and trauma
from the criminal justice system. Additionally, variables associated with sexual offending
grouped with Component 4: Aggression & behavioral problems rather than Component 3:
Justice-system involvement; these variables also did not load onto a separate component specific
to sexual behavior problems. This is notable as these variables were included in the PCA because
prior literature has not indicated whether problematic sexual behaviors independently increase
risk for polypharmacy. The current results suggest that sexual behavior problems may not
significantly differ from general behavioral problems with regard to polypharmacy risk.
However, some variables related to sexual offending were omitted from later iterations of the
PCA as they did not evidence meaningfully high factor loadings. To better investigate this
question, studies comparing polypharmacy practices across youth with and without sexually
abusive behaviors in the same sample should be conducted.
With regard to polypharmacy outcomes, different components were significantly
associated with various outcomes. Component 1: Psychiatric concerns and Component 2: ACEs
were significantly associated with increasing numbers of current medication classes, as well as
current antipsychotic use. Increased and more serious psychiatric symptoms perhaps suggest a
more complex presentation, which may require more forms of medication to treat each
presenting concern. Previous analyses indicated that antipsychotics were not used to treat solely
psychotic symptoms, but rather a wide variety of behavior-related diagnoses, which are also
represented within Component 1. Additionally, Component 1 included the total number of outof-home placements and psychiatric inpatient admissions, each of which could constitute a
disruption in clinical care, thus increasing risk for polypharmacy (Jokanovic et al., 2015;
Medhekar et al., 2019). Component 2 measured trauma, maltreatment, dysfunction, and
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indicators of residential instability. The association between Component 2 and increasing
numbers of medication classes is consistent with the breadth of literature concerning systemsinvolved youth and risk for polypharmacy (Brenner et al., 2014; Longhofer et al., 2011).
Component 1: Psychiatric concerns and Component 3: Justice-system involvement were
significantly associated with current ADHD/stimulant medications. These medications typically
address impulsivity and hyperactivity, which psychiatric concerns may encompass. Impulsivity
may also increase risk of delinquency, as individuals who act impulsively may not think through
consequences of their actions and be more likely to recidivate. Notably, Component 4:
Aggression & behavioral problems was not significantly related to ADHD/stimulant medication
prescription. This is surprising since behavioral impulsivity is a feature of ADHD and would
presumably lead to a relationship between the two. However, if participants have been prescribed
such medications and experience effective control of their ADHD, it may lead to fewer of the
behavioral problems included within Component 4.
It is also worth noting that some hypothesized models did not reach significance in ways
that were unexpected. Component 4: Aggression & behavioral problems was not significantly
associated with polypharmacy or any specific medication class. One possibility is that the
behavior problems most relevant to prescribing practices were included within Component 1
rather than Component 4. Another consideration is the high base rates of aggression and
behavioral issues in this sample. Sometimes high base rates (and thus, lack of heterogeneity) may
lead to insignificant findings, as it is difficult to discriminate effects of behaviors that are
frequently characteristic of the sample. That is, if the majority of or all participants evidenced
aggression, such variables are not as informative for research questions that attempt to find
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differences amongst subgroups. A third possibility is that the other components were simply
more predictive of the dependent variables chosen.
Changes in Prescribing
Past research has found that adolescents in treatment facilities are at risk of having
medications added rather than subtracted from their regimen (van Wattum et al., 2013), and this
was supported in the current study. More participants experienced an increase rather than a
decrease in the number of medication classes prescribed after being admitted to the treatment
facility. However, the prevalence rate of participants with no cumulative change (37.8%, n =
105) was almost as high as that of participants who experienced an increase (38.9%, n = 108).
Though there are positive outcomes associated with decreasing polypharmacy (van Wattum et
al., 2013), especially given the increase in risk for ADRs as medications increase, sometimes
polypharmacy is clinically indicated or even necessary for proper care. Further, an increase in
medication classes for a patient may be a temporary solution or may suitably address a problem
that has previously been less effectively managed. It is noteworthy that over one-fifth of
participants (22%, n = 65) experienced a decrease in medication classes post-admission, as well
as the fact that less than half of participants experienced an increase.
The current study did not find significant associations with the change in medication
classes post-admission. This was unexpected given that there were significant findings for other
outcomes of polypharmacy, and previous research has linked increased rates of polypharmacy to
admission to treatment facilities, hospitalizations, and incarceration/justice-system involvement
(Duffy et al., 2005; Griffiths et al., 2012; van Wattum et al., 2013). Other factors not explored in
the current study may be predictive of such changes.
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Summary & Clinical Implications
This study was the first to examine psychotropic polypharmacy in adolescents who have
engaged in sexually abusive behaviors, a population that exhibits multiple vulnerabilities to such
practices. Results show evidence of polypharmacy for these youth, with the majority of youth
being prescribed more than one class of psychotropic medication. Additionally, many were
prescribed antipsychotics for off-label purposes. Many participants initiated psychotropic
medication use at young ages, which researchers and professional organizations caution against
due to the risk for potential harm. Psychiatric complexity, instances of trauma and household
dysfunction, and behavioral issues appeared to be most predictive of risk for polypharmacy, all
of which are common amongst justice-involved youth (Fox et al., 2015; Huefner et al., 2017;
Lyons et al., 2013). Results also supported previous findings that youth who have engaged in
sexually abusive behaviors are particularly susceptible to trauma, mental health concerns, and
residential instability.
Polypharmacy is a potential concern that can be added to the long list of vulnerabilities
for youth who have engaged in sexually abusive behaviors. Their experiences are often
characterized by repeated traumatic events and extreme instability, which can lead to behavior
problems and psychological distress. Chronic patterns of changing medications only add to the
unpredictable and chaotic nature of their lives. Especially for youth who exhibit aggression and
disobedience, providing coping skills and behavioral interventions should be emphasized over
the use of medications like antipsychotics that carry a range of physical and psychological risks.
Whether the treatment avenues chosen are pharmacological, psychosocial, or both, it is
impossible to ignore the effects of cumulative trauma for justice-involved youth. Researchers
and clinicians alike have called for a trauma-informed approach to treatment within the juvenile
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justice system in which practitioners and staff working with these youth are educated and trained
on the effects of trauma (Skinner-Osei et al., 2019). This includes viewing maladaptive,
problematic behavior through the lens of trauma, and avoiding the repetition of disempowering
dynamics in the helping relationship (Levenson, 2019). Guidelines also encourage youth and
their families to play a more active role in the youth’s treatment (Branson et al., 2017). These
suggestions correspond to recommendations for prescribing psychotropic medications in youth
(e.g., proper psychological assessment and screening, informed consent with youth and caregiver
present, utilizing evidence-based practices when available).
Another way to improve treatment within the juvenile justice system is through the
utilization of multidisciplinary team-based care. Calls for such collaboration are not new, as
researchers have noted the potential benefits of combining agencies and professionals to
streamline care for justice-involved youth (O’Hara et al., 2019; Unnithan & Johnston, 2012).
Mental health professionals may work alongside court representatives, social workers, and
medical prescribers to best assist these youth and minimize disruptions in care. This not only
allows for psychologists to encourage trauma-informed care amongst the various agencies that
contact youth, but it could also potentially decrease rates of polypharmacy by including
prescribers within the team. Psychiatrists and primary care physicians often practice the most
independently, and they may have less training in the impact of trauma on behavior or the
effectiveness of behavioral interventions. Improving treatment for justice-involved youth could
not only increase the quality of their daily lives but perhaps even prevent future revictimization
or recidivism.
In conclusion, polypharmacy is an issue about which prescribers and patients alike should
be concerned. Though polypharmacy may be warranted at times, there are significant risks for
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ADRs when taking psychotropic medications, especially when patients are children. Adolescents
who have engaged in sexually abusive behaviors are a population uniquely at risk for
polypharmacy, among other vulnerabilities for detrimental outcomes. They are also commonly
prescribed medications with unwanted side effects and possible ADRs, including antipsychotics.
The current study suggests that psychiatric complexity, behavioral issues, and trauma/instability
are all important considerations when prescribing medications to these youth. Further research
regarding polypharmacy in vulnerable youth is needed to help inform clinical practice and
policy.
Limitations
There are limitations in the current study that should be acknowledged. This is the first
study to my knowledge that investigates polypharmacy in this specific population, so some
hypotheses and results were exploratory rather than confirmatory. Additionally, other variables
not included in this study may be pertinent to polypharmacy practices in this population. There
are inherent limitations due to the nature of archival data collection. For example, follow-up
questions or clarification of confusing data could not be asked of participants, as data were
collected from archival records. Information available for each participant could be impacted by
their previous placements, caregivers, or providers; this is notable given the level of residential
instability of the youth in this sample. Information recorded could also be inaccurate, or it may
be affected by self-report/memory bias of young participants or caregivers. Further, data were
entered into the record by different people over time.
The archival data collection captured a time period of ten years during which participants
entered the treatment facility, and historical records of previous medications dated back even
further. Thus, this data is representative of the practices of multiple prescribers at different time
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points. This could result in variations in polypharmacy practices, as each provider may have
different preferences regarding medication classes, specific medications, or the practicality/risks
of polypharmacy. Relatedly, prescribing trends and available medications could vary over this
ten-year span. New medications or updated prescribing guidelines could affect what and how
providers prescribe.
Further research specific to adolescents who have engaged in sexually abusive behaviors
is needed, as these results represent a single sample from a distinct geographic location. The
current sample was predominantly White, and only five participants were female. This limits the
generalizability of results to other female adolescents or to specific non-White ethnicities given
that race was collapsed into White and non-White. Another limitation is the lack of a comparison
group for this sample. Inclusion of justice-involved youth without histories of sexual offending
could potentially impact the PCA and outcomes regarding aggression. This would also shed light
on potential differences amongst youth with and without sexually abusive behaviors with regard
to prescribing practices.
Age of initiation of psychotropic medications was a polypharmacy-related outcome
variable with a significant amount of missing data (44%), which greatly limited statistical power
of analyses including this outcome variable. This is likely related to the limitations of archival
data collection mentioned previously. The information available indicated that a proportion of
participants began psychotropic medications at a very young age, but the distribution of this
variable may be much more skewed in larger samples with fewer instances of missing data.
Lastly, this study examined polypharmacy through the measure of medication classes rather than
individual medications. Though between-class polypharmacy may pose greater risk of
detrimental outcomes, different indications of polypharmacy could be measured if changes of
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medication within the same class were included. Regardless of measurement, future studies
should be explicit in the definition of polypharmacy utilized, including designations of withinclass or between-class.
Conclusion
This study examined psychotropic polypharmacy practices within a sample of
adolescents who have engaged in sexually abusive behaviors, a unique population at risk for a
variety of detrimental outcomes. Polypharmacy was common in the sample, with many
participants being prescribed medications associated with high risk for ADRs (i.e.,
antipsychotics), oftentimes for off-label use. A surprising number of individuals began taking
psychotropic medications at a very young age, increasing their risk for neurodevelopmental
problems and chronic use of such medications. Some differences were evident amongst different
diagnostic categories, though general trends indicated that youth with diagnoses associated with
behavioral problems were highly medicated. PCA results revealed groupings of predictor
variables associated with past literature. Some components were significantly associated with
polypharmacy outcomes, while other hypotheses yielded insignificant results. Importantly, this is
the first study of its kind to examine such practices in this niche population. Study findings
present unique considerations for treatment and policies regarding justice-involved youth, as well
as general psychotropic prescribing practices in pediatric populations.
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